Advertisement

Index by author

August 01, 1989; Volume 36,Issue 2

A

  1. Abrass, I B

    1. Beta 2-adrenergic receptor regulation after transfection into a cell line deficient in the cAMP-dependent protein kinase.
      J M Allen, I B Abrass and R D Palmiter
      Molecular Pharmacology August 1989, 36 (2) 248-255;

  2. Allen, J M

    1. Beta 2-adrenergic receptor regulation after transfection into a cell line deficient in the cAMP-dependent protein kinase.
      J M Allen, I B Abrass and R D Palmiter
      Molecular Pharmacology August 1989, 36 (2) 248-255;

  3. Artman, M

    1. Analysis of the binding sites for the cardiotonic phosphodiesterase inhibitor [3H]LY186126 in ventricular myocardium.
      M Artman, D W Robertson, L Mahony and W J Thompson
      Molecular Pharmacology August 1989, 36 (2) 302-311;

B

  1. Barrett, R W

    1. Type-A cholecystokinin binding sites in cow brain: characterization using (-)-[3H]L364718 membrane binding assays.
      R W Barrett, M E Steffey and C A Wolfram
      Molecular Pharmacology August 1989, 36 (2) 285-290;

  2. Batist, G

    1. Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line.
      G Batist, S Torres-Garcia, J M Demuys, D Greene, S Lehnert, M Rochon and L Panasci
      Molecular Pharmacology August 1989, 36 (2) 224-230;

  3. Bloomquist, J R

    1. Activation of sodium channels and inhibition of [3H]batrachotoxinin A-20-alpha-benzoate binding by an N-alkylamide neurotoxin.
      J A Ottea, G T Payne, J R Bloomquist and D M Soderlund
      Molecular Pharmacology August 1989, 36 (2) 280-284;

  4. Bolger, G T

    1. Radiation inactivation reveals discrete cation binding sites that modulate dihydropyridine binding sites.
      G T Bolger, P Skolnick and E S Kempner
      Molecular Pharmacology August 1989, 36 (2) 327-332;

  5. Bonhaus, D W

    1. Glycine regulation of the N-methyl-D-aspartate receptor-gated ion channel in hippocampal membranes.
      D W Bonhaus, G C Yeh, L Skaryak and J O McNamara
      Molecular Pharmacology August 1989, 36 (2) 273-279;

  6. Bresnick, E H

    1. Characterization of 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated decreases in dexamethasone binding to rat hepatic cytosolic glucocorticoid receptor.
      G I Sunahara, G W Lucier, Z McCoy, E H Bresnick, E R Sanchez and K G Nelson
      Molecular Pharmacology August 1989, 36 (2) 239-247;

C

  1. Chou, T C

    1. Analogues of taurine as stimulators and inhibitors of ATP-dependent calcium ion uptake in rat retina: combination kinetics.
      J B Lombardini, S M Liebowitz and T C Chou
      Molecular Pharmacology August 1989, 36 (2) 256-264;

  2. Cragoe, E J

    1. Inhibition of monoamine oxidase by analogues of amiloride.
      V Palatý and E J Cragoe
      Molecular Pharmacology August 1989, 36 (2) 296-301;

D

  1. Danenberg, K D

    1. Activity of thymidylate synthetase and its inhibition by 5-fluorouracil in highly enzyme-overproducing cells resistant to 10-propargyl-5,8-dideazafolate.
      K D Danenberg and P V Danenberg
      Molecular Pharmacology August 1989, 36 (2) 219-223;

  2. Danenberg, P V

    1. Activity of thymidylate synthetase and its inhibition by 5-fluorouracil in highly enzyme-overproducing cells resistant to 10-propargyl-5,8-dideazafolate.
      K D Danenberg and P V Danenberg
      Molecular Pharmacology August 1989, 36 (2) 219-223;

  3. Demuys, J M

    1. Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line.
      G Batist, S Torres-Garcia, J M Demuys, D Greene, S Lehnert, M Rochon and L Panasci
      Molecular Pharmacology August 1989, 36 (2) 224-230;

F

  1. Fridland, A

    1. Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells.
      M A Johnson and A Fridland
      Molecular Pharmacology August 1989, 36 (2) 291-295;

G

  1. Goldstein, A

    1. Multiple opioid receptors: ligand selectivity profiles and binding site signatures.
      A Goldstein and A Naidu
      Molecular Pharmacology August 1989, 36 (2) 265-272;

  2. Greene, D

    1. Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line.
      G Batist, S Torres-Garcia, J M Demuys, D Greene, S Lehnert, M Rochon and L Panasci
      Molecular Pharmacology August 1989, 36 (2) 224-230;

H

  1. Harrison, J H

    1. Acute pulmonary toxicity of bleomycin: DNA scission and matrix protein mRNA levels in bleomycin-sensitive and -resistant strains of mice.
      J H Harrison, D G Hoyt and J S Lazo
      Molecular Pharmacology August 1989, 36 (2) 231-238;

  2. Hoyt, D G

    1. Acute pulmonary toxicity of bleomycin: DNA scission and matrix protein mRNA levels in bleomycin-sensitive and -resistant strains of mice.
      J H Harrison, D G Hoyt and J S Lazo
      Molecular Pharmacology August 1989, 36 (2) 231-238;

I

  1. Insel, P A

    1. Defining the role of protein kinase C in epinephrine- and bradykinin-stimulated arachidonic acid metabolism in Madin-Darby canine kidney cells.
      B A Weiss, S R Slivka and P A Insel
      Molecular Pharmacology August 1989, 36 (2) 317-326;

J

  1. Johnson, M A

    1. Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells.
      M A Johnson and A Fridland
      Molecular Pharmacology August 1989, 36 (2) 291-295;

K

  1. Kempner, E S

    1. Radiation inactivation reveals discrete cation binding sites that modulate dihydropyridine binding sites.
      G T Bolger, P Skolnick and E S Kempner
      Molecular Pharmacology August 1989, 36 (2) 327-332;

  2. Konno, K

    1. Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
      T Yokota, K Konno, S Mori, S Shigeta, M Kumagai, Y Watanabe and H Machida
      Molecular Pharmacology August 1989, 36 (2) 312-316;

  3. Kumagai, M

    1. Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
      T Yokota, K Konno, S Mori, S Shigeta, M Kumagai, Y Watanabe and H Machida
      Molecular Pharmacology August 1989, 36 (2) 312-316;

L

  1. Lazo, J S

    1. Acute pulmonary toxicity of bleomycin: DNA scission and matrix protein mRNA levels in bleomycin-sensitive and -resistant strains of mice.
      J H Harrison, D G Hoyt and J S Lazo
      Molecular Pharmacology August 1989, 36 (2) 231-238;

  2. Lehnert, S

    1. Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line.
      G Batist, S Torres-Garcia, J M Demuys, D Greene, S Lehnert, M Rochon and L Panasci
      Molecular Pharmacology August 1989, 36 (2) 224-230;

  3. Liebowitz, S M

    1. Analogues of taurine as stimulators and inhibitors of ATP-dependent calcium ion uptake in rat retina: combination kinetics.
      J B Lombardini, S M Liebowitz and T C Chou
      Molecular Pharmacology August 1989, 36 (2) 256-264;

  4. Lombardini, J B

    1. Analogues of taurine as stimulators and inhibitors of ATP-dependent calcium ion uptake in rat retina: combination kinetics.
      J B Lombardini, S M Liebowitz and T C Chou
      Molecular Pharmacology August 1989, 36 (2) 256-264;

  5. Lucier, G W

    1. Characterization of 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated decreases in dexamethasone binding to rat hepatic cytosolic glucocorticoid receptor.
      G I Sunahara, G W Lucier, Z McCoy, E H Bresnick, E R Sanchez and K G Nelson
      Molecular Pharmacology August 1989, 36 (2) 239-247;

M

  1. Machida, H

    1. Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
      T Yokota, K Konno, S Mori, S Shigeta, M Kumagai, Y Watanabe and H Machida
      Molecular Pharmacology August 1989, 36 (2) 312-316;

  2. Mahony, L

    1. Analysis of the binding sites for the cardiotonic phosphodiesterase inhibitor [3H]LY186126 in ventricular myocardium.
      M Artman, D W Robertson, L Mahony and W J Thompson
      Molecular Pharmacology August 1989, 36 (2) 302-311;

  3. McCoy, Z

    1. Characterization of 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated decreases in dexamethasone binding to rat hepatic cytosolic glucocorticoid receptor.
      G I Sunahara, G W Lucier, Z McCoy, E H Bresnick, E R Sanchez and K G Nelson
      Molecular Pharmacology August 1989, 36 (2) 239-247;

  4. McNamara, J O

    1. Glycine regulation of the N-methyl-D-aspartate receptor-gated ion channel in hippocampal membranes.
      D W Bonhaus, G C Yeh, L Skaryak and J O McNamara
      Molecular Pharmacology August 1989, 36 (2) 273-279;

  5. Mori, S

    1. Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
      T Yokota, K Konno, S Mori, S Shigeta, M Kumagai, Y Watanabe and H Machida
      Molecular Pharmacology August 1989, 36 (2) 312-316;

N

  1. Naidu, A

    1. Multiple opioid receptors: ligand selectivity profiles and binding site signatures.
      A Goldstein and A Naidu
      Molecular Pharmacology August 1989, 36 (2) 265-272;

  2. Nelson, K G

    1. Characterization of 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated decreases in dexamethasone binding to rat hepatic cytosolic glucocorticoid receptor.
      G I Sunahara, G W Lucier, Z McCoy, E H Bresnick, E R Sanchez and K G Nelson
      Molecular Pharmacology August 1989, 36 (2) 239-247;

O

  1. Ottea, J A

    1. Activation of sodium channels and inhibition of [3H]batrachotoxinin A-20-alpha-benzoate binding by an N-alkylamide neurotoxin.
      J A Ottea, G T Payne, J R Bloomquist and D M Soderlund
      Molecular Pharmacology August 1989, 36 (2) 280-284;

P

  1. Palatý, V

    1. Inhibition of monoamine oxidase by analogues of amiloride.
      V Palatý and E J Cragoe
      Molecular Pharmacology August 1989, 36 (2) 296-301;

  2. Palmiter, R D

    1. Beta 2-adrenergic receptor regulation after transfection into a cell line deficient in the cAMP-dependent protein kinase.
      J M Allen, I B Abrass and R D Palmiter
      Molecular Pharmacology August 1989, 36 (2) 248-255;

  3. Panasci, L

    1. Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line.
      G Batist, S Torres-Garcia, J M Demuys, D Greene, S Lehnert, M Rochon and L Panasci
      Molecular Pharmacology August 1989, 36 (2) 224-230;

  4. Parsons, S M

    1. Inhibition of acetylcholine storage by acetylcholine analogs in vitro.
      G A Rogers and S M Parsons
      Molecular Pharmacology August 1989, 36 (2) 333-341;

  5. Payne, G T

    1. Activation of sodium channels and inhibition of [3H]batrachotoxinin A-20-alpha-benzoate binding by an N-alkylamide neurotoxin.
      J A Ottea, G T Payne, J R Bloomquist and D M Soderlund
      Molecular Pharmacology August 1989, 36 (2) 280-284;

R

  1. Robertson, D W

    1. Analysis of the binding sites for the cardiotonic phosphodiesterase inhibitor [3H]LY186126 in ventricular myocardium.
      M Artman, D W Robertson, L Mahony and W J Thompson
      Molecular Pharmacology August 1989, 36 (2) 302-311;

  2. Rochon, M

    1. Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line.
      G Batist, S Torres-Garcia, J M Demuys, D Greene, S Lehnert, M Rochon and L Panasci
      Molecular Pharmacology August 1989, 36 (2) 224-230;

  3. Rogers, G A

    1. Inhibition of acetylcholine storage by acetylcholine analogs in vitro.
      G A Rogers and S M Parsons
      Molecular Pharmacology August 1989, 36 (2) 333-341;

S

  1. Sanchez, E R

    1. Characterization of 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated decreases in dexamethasone binding to rat hepatic cytosolic glucocorticoid receptor.
      G I Sunahara, G W Lucier, Z McCoy, E H Bresnick, E R Sanchez and K G Nelson
      Molecular Pharmacology August 1989, 36 (2) 239-247;

  2. Shigeta, S

    1. Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
      T Yokota, K Konno, S Mori, S Shigeta, M Kumagai, Y Watanabe and H Machida
      Molecular Pharmacology August 1989, 36 (2) 312-316;

  3. Skaryak, L

    1. Glycine regulation of the N-methyl-D-aspartate receptor-gated ion channel in hippocampal membranes.
      D W Bonhaus, G C Yeh, L Skaryak and J O McNamara
      Molecular Pharmacology August 1989, 36 (2) 273-279;

  4. Skolnick, P

    1. Radiation inactivation reveals discrete cation binding sites that modulate dihydropyridine binding sites.
      G T Bolger, P Skolnick and E S Kempner
      Molecular Pharmacology August 1989, 36 (2) 327-332;

  5. Slivka, S R

    1. Defining the role of protein kinase C in epinephrine- and bradykinin-stimulated arachidonic acid metabolism in Madin-Darby canine kidney cells.
      B A Weiss, S R Slivka and P A Insel
      Molecular Pharmacology August 1989, 36 (2) 317-326;

  6. Soderlund, D M

    1. Activation of sodium channels and inhibition of [3H]batrachotoxinin A-20-alpha-benzoate binding by an N-alkylamide neurotoxin.
      J A Ottea, G T Payne, J R Bloomquist and D M Soderlund
      Molecular Pharmacology August 1989, 36 (2) 280-284;

  7. Steffey, M E

    1. Type-A cholecystokinin binding sites in cow brain: characterization using (-)-[3H]L364718 membrane binding assays.
      R W Barrett, M E Steffey and C A Wolfram
      Molecular Pharmacology August 1989, 36 (2) 285-290;

  8. Sunahara, G I

    1. Characterization of 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated decreases in dexamethasone binding to rat hepatic cytosolic glucocorticoid receptor.
      G I Sunahara, G W Lucier, Z McCoy, E H Bresnick, E R Sanchez and K G Nelson
      Molecular Pharmacology August 1989, 36 (2) 239-247;

T

  1. Thompson, W J

    1. Analysis of the binding sites for the cardiotonic phosphodiesterase inhibitor [3H]LY186126 in ventricular myocardium.
      M Artman, D W Robertson, L Mahony and W J Thompson
      Molecular Pharmacology August 1989, 36 (2) 302-311;

  2. Torres-Garcia, S

    1. Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line.
      G Batist, S Torres-Garcia, J M Demuys, D Greene, S Lehnert, M Rochon and L Panasci
      Molecular Pharmacology August 1989, 36 (2) 224-230;

W

  1. Watanabe, Y

    1. Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
      T Yokota, K Konno, S Mori, S Shigeta, M Kumagai, Y Watanabe and H Machida
      Molecular Pharmacology August 1989, 36 (2) 312-316;

  2. Weiss, B A

    1. Defining the role of protein kinase C in epinephrine- and bradykinin-stimulated arachidonic acid metabolism in Madin-Darby canine kidney cells.
      B A Weiss, S R Slivka and P A Insel
      Molecular Pharmacology August 1989, 36 (2) 317-326;

  3. Wolfram, C A

    1. Type-A cholecystokinin binding sites in cow brain: characterization using (-)-[3H]L364718 membrane binding assays.
      R W Barrett, M E Steffey and C A Wolfram
      Molecular Pharmacology August 1989, 36 (2) 285-290;

Y

  1. Yeh, G C

    1. Glycine regulation of the N-methyl-D-aspartate receptor-gated ion channel in hippocampal membranes.
      D W Bonhaus, G C Yeh, L Skaryak and J O McNamara
      Molecular Pharmacology August 1989, 36 (2) 273-279;

  2. Yokota, T

    1. Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
      T Yokota, K Konno, S Mori, S Shigeta, M Kumagai, Y Watanabe and H Machida
      Molecular Pharmacology August 1989, 36 (2) 312-316;
Back to top

In this issue

Advertisement